SZ003 / Guangdong ProCapZoom Biosci - LARVOL DELTA

A novel antibody against GPIbα inhibits platelet function and thrombosis without increasing bleeding. (PubMed, Int J Biol Macromol) - "The Fab fragment of anti-human GPIbα humanized antibody SZ003 effectively inhibited GPIbα receptor-mediated platelet activation and thrombosis in vivo without leading to thrombocytopenia and bleeding. Therefore, SZ003-Fab has clinical value as a novel antithrombotic drug to treat arterial thrombus-related diseases."

Journal • Cardiovascular • Hematological Disorders • Thrombocytopenia • Thrombosis

Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P=N/A | N=8 | Terminated | Sponsor: Shantou University Medical College | N=12 ➔ 8 | Trial completion date: May 2025 ➔ Sep 2024 | Recruiting ➔ Terminated | Trial primary completion date: May 2025 ➔ Sep 2024; Failed to recruit more volunteers

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3

Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P=N/A | N=12 | Recruiting | Sponsor: Shantou University Medical College | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3

Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P=N/A | N=12 | Not yet recruiting | Sponsor: Shantou University Medical College

New trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3